Connect Biopharma Holdings Limited (CNTB) Stock Forecast
CNTB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.88 / 5 from 8 analysts
- Price target
- $5.88 average of analyst targets
- Upside to target
- +548.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.27
- 52-week range
- $0.87 – $3.69
CNTB analyst ratings
8 analystsNumber of analysts at each rating.
CNTB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CNTB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.32 | −$0.19 | −$0.31 | +16.8% | 5 |
| Current fiscal year (2026) | −$0.98 | −$1.22 | −$0.72 | −$1.00 | +2.4% | 5 |
| Next fiscal year (2027) | −$0.77 | −$1.27 | −$0.42 | −$0.98 | +20.9% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CNTB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.5M | $0 | $33.6M | +3,878.9% | 8 |
| Current fiscal year (2026) | $50.3M | $19.4M | $120.1M | +11,291.5% | 8 |
| Next fiscal year (2027) | $87.6M | $0 | $172.3M | +74.3% | 8 |
CNTB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CNTB revenue: reported and forecast
CNTB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.27 | −$0.26 | −$0.25 | −$0.26 | −6.8% | 1 up · 1 down |
| Current fiscal year (2026) | −$1.06 | −$1.04 | −$1.00 | −$0.97 | −$0.98 | −7.8% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.94 | −$0.92 | −$0.89 | −$0.72 | −$0.77 | −17.5% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CNTB earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; CNTB beat in 6 of 10.
What analysts expect from CNTB
8 analysts cover Connect Biopharma; their consensus rating is strong buy (4.88 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.88, 548.2% above the latest close of $0.91. Analysts expect earnings of −$0.98 per share for 2026, +2.4% from a year earlier. For 2027 the average estimate is −$0.77 per share on revenue of $87.6 million. Connect Biopharma beat the EPS estimate in 6 of the last 10 quarters.
Related: CNTB income statement, CNTB key metrics, CNTB chart. See the CNTB stock overview for the latest quote and news.
CNTB forecast FAQ
What is Connect Biopharma's price target?
The average analyst price target for Connect Biopharma is $5.88, 548.2% above the latest close of $0.91.
Is Connect Biopharma a buy, hold or sell?
Of 8 analysts covering Connect Biopharma, 7 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Connect Biopharma's EPS forecast?
Analysts forecast −$0.98 per share for 2026 (range −$1.22 to −$0.72); for 2027 the estimate is −$0.77.
What is Connect Biopharma's revenue forecast?
The average revenue estimate for 2026 is $50.3 million, growth of 11,291.5%; for 2027 it is $87.6 million.
When does Connect Biopharma report earnings?
Connect Biopharma is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.27.
Does Connect Biopharma usually beat earnings estimates?
Connect Biopharma reported EPS at or above the analyst estimate in 6 of the last 10 quarters.